| Sauer, Martin |
| Recruiting | 2 | 142 | Europe | ARTICE | Artcline GmbH, Zentrum für Klinische Studien Jena, CRO Kottmann | Sepsis, Severe | 12/24 | 05/25 | | |
| Recruiting | 2 | 200 | Europe | Pentaglobin®/Standard of Care | RWTH Aachen University, Biotest | Peritonitis, Sepsis, Septic Shock | 09/27 | 03/28 | | |
NCT04277598: A Study to Evaluate Safety and Efficacy of APO-2 at Three Different Doses in Patients With Diabetic Foot Ulcer |
|
|
| Completed | 1/2 | 159 | Europe, RoW | APO-2, Placebo | Aposcience AG, FGK Clinical Research GmbH | Diabetic Foot Ulcer (DFU) | 12/23 | 12/23 | | |
ReActIF- LTO, NCT06143137: Recovery From Acute Immune Failure in Septic Shock by Immune Cell Extracorporeal Therapy - Observational Long-term Outcome Follow up |
|
|
| Recruiting | N/A | 142 | Europe | | Artcline GmbH, ZKS Jena | Severe Sepsis | 12/29 | 02/30 | | |
| Heidel, Florian |
NCT03897127: Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics |
|
|
| Recruiting | 3 | 882 | Europe | Cytarabine, Daunorubicin, CPX-351 | University of Ulm, Jazz Pharmaceuticals | Acute Myeloid Leukemia | 03/24 | 03/24 | | |
LENNON, NCT05384691: Efficacy of Luspatercept in ESA-naive LR-MDS Patients With or Without Ring Sideroblasts Who do Not Require Transfusions |
|
|
| Recruiting | 2 | 213 | Europe | Luspatercept Injection, LUS | University of Leipzig, Celgene Corporation | Myelodysplastic Syndromes, Anemia | 07/26 | 07/27 | | |
| Recruiting | 1/2 | 199 | Europe, Canada, US | Ziftomenib | Kura Oncology, Inc. | Advanced Malignant Neoplasm, Acute Myeloid Leukemia, Mixed Lineage Leukemia, Mixed Lineage Acute Leukemia, Acute Leukemia of Ambiguous Lineage, Mixed Phenotype Acute Leukemia | 09/24 | 09/25 | | |
| Welte, Tobias |
| Recruiting | 3 | 390 | Europe, RoW | Trimodulin, BT588, Placebo (human albumin 1%) | Biotest | Respiratory Infection, Pneumonia, Community-acquired Pneumonia, Acute Respiratory Distress Syndrome, COVID-19, Viral Pneumonia, Bacterial Pneumonia, Fungal Pneumonia | 08/25 | 08/25 | | |
| Recruiting | 3 | 526 | Europe, US, RoW | Reparixin, Repertaxin L-lysine salt, Placebo, Matched placebo | Dompé Farmaceutici S.p.A | Infectious Pneumonia, Severe COVID-19 | 09/24 | 10/24 | | |
ESsCAPE, NCT05722938: Efficacy and Safety of Trimodulin (BT588) in Subjects With Severe Community-acquired Pneumonia (sCAP) |
|
|
| Recruiting | 3 | 590 | Europe, US, RoW | Trimodulin, BT588, Placebo (human albumin 1%) | Biotest | Community-acquired Pneumonia | 02/25 | 04/25 | | |
| Recruiting | 3 | 1700 | Europe, Canada, Japan, US, RoW | GSK3511294 (Depemokimab), Mepolizumab, Benralizumab, Placebo, Standard of care (SoC), Pre-filled Syringes (PFS) | GlaxoSmithKline, Iqvia Pty Ltd | Asthma | 09/25 | 09/25 | | |
|
| Recruiting | N/A | 2050 | Europe | prospective observational cohort study | GlaxoSmithKline | Pulmonary Disease, Chronic Obstructive | 04/24 | 04/24 | | |
TRIBE, NCT05652439: PASS to Assess Cardiovascular and Cerebrovascular Events in COPD Patients Initiating Fixed Triple Therapy (DPI or pMDI) |
|
|
| Recruiting | N/A | 25000 | Europe | Observational retrospective data collection, No treatment given | Chiesi Farmaceutici S.p.A. | Chronic Obstructive Pulmonary Disease | 08/26 | 08/26 | | |
| Muller, Thomas |
NCT05357989: A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PD |
|
|
| Completed | 3 | 523 | Europe, US | buntanetap/posiphen, Posiphen Tartrate, ANVS401, Placebo | Annovis Bio Inc., TFS Trial Form Support | Parkinson's Disease, Idiopathic | 12/23 | 12/23 | | |
| Recruiting | N/A | 300 | Europe, Canada, US, RoW | MMDx, Prospera, transplant patient blood sample, HLA antibody | University of Alberta, Natera, Inc., One Lambda | Kidney Transplant Rejection | 12/24 | 12/25 | | |
